GlaxoSmithKline Says FDA Rejected Zofran Birth Defects
GlaxoSmithKline argued Thursday that it cannot be held liable for birth defects caused after pregnant women were prescribed its postoperative nausea drug Zofran because the U.S. Food and Drug Administration has...To view the full article, register now.
Already a subscriber? Click here to view full article